

Amyloid and tau PET in relation to longitudinal change in subjective cognitive complaints among cognitively normal individuals

Alisa Bannerjee¹, Wendy Elkins¹, Susan M. Resnick¹, Murat Bilgel¹

¹ Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland,
USA

Corresponding author: Murat Bilgel, murat.bilgel@nih.gov, 251 Bayview Blvd., Suite 100
Rm 04B329, Baltimore, MD, 21224 USA

Keywords: Tau; amyloid; Alzheimer's disease; subjective cognitive decline; longitudinal

Abstract

Background and Objectives: Subjective cognitive complaints often precede declines in objective measures of cognitive performance and may facilitate the early diagnosis of cognitive impairment. This study examined whether amyloid and tau pathology are associated with level and longitudinal change in subjective cognitive complaints among cognitively normal individuals, and compared these associations to those observed with objective neuropsychological measures of verbal episodic memory performance.

Methods: Amyloid and tau pathology were measured by ^{11}C -Pittsburgh compound B (PiB) and ^{18}F -flortaucipir (FTP) PET scans, respectively. FTP PET regions of interest (ROIs) included the entorhinal cortex, hippocampus, parahippocampal gyrus, and inferior temporal gyrus. Subjective cognitive complaints were assessed using the Cognitive Failures Questionnaire (CFQ). California Verbal Learning Test (CVLT) immediate and long-delayed free recall scores were used to quantify objective memory performance. We examined the association of PET measures with rates of change in CFQ and verbal memory within 5 years of the PET scans using linear mixed effects models.

Results: We analyzed data for 92 cognitively normal participants in the Baltimore Longitudinal Study of Aging (BLSA). In analyses that included both amyloid positivity and regional tau burden as predictors greater parahippocampal tau standardized uptake value ratio (SUVR) was associated with higher CFQ, indicating greater subjective cognitive complaints (estimate = 0.178, SE = 0.0821, $p = 0.033$). Greater entorhinal tau SUVR corresponded to an attenuated increase in CFQ over time (estimate = -0.064, SE = 0.0296, p

= 0.035), whereas greater hippocampal tau SUVR was associated with a steeper longitudinal decline in memory (estimate = -0.0293, SE = 0.0135, $p = 0.032$).

Discussion: Individuals with higher levels of tau pathology may experience greater levels of subjective cognitive complaints. Such associations are detectable among cognitively normal individuals even in the absence of marked neuropathology-associated differences in neuropsychological assessments of verbal episodic memory, suggesting that subjective cognitive complaints may serve as early indicators of accumulating cerebral tau pathology.

1 Introduction

Subjective cognitive complaints are individuals' perceived and self-reported memory complaints, or memory complaints reported by a close relative or friend who has observed changes in the individual's cognition [1]. The 2018 National Institute of Aging – Alzheimer's Association Alzheimer's Disease (AD) Research Framework [2] as well as the Alzheimer's Association Workgroup's revised criteria for diagnosis and staging of Alzheimer's disease [3] identify clinical stage 2 as the time when an individual is experiencing subtle cognitive change, which can be measured by subjective cognitive complaints, but does not show cognitive impairment on objective testing. Some studies have shown that participants reporting higher subjective cognitive complaints had worse scores on neuropsychological testing [4,5] and faster rates of decline in neuropsychological testing [6]. In addition, participants with subjective cognitive complaints are at a higher risk for progressing to dementia versus those without these complaints [7–9]. However, other studies did not find

an association between subjective cognitive complaints and objective cognitive assessments [10,11].

The revised criteria for AD include definitions for both the clinical and biological stages of AD. The biological staging of individuals is based on the presence of amyloid and tau, and suggest the typical expected progression trajectory for those who are in clinical stage 2, defined by subtle cognitive decline including subjective decline, to also be in biological stage B, as characterized by the presence of amyloid plaques and medial temporal tau [3].

This is supported by research showing that individuals with subjective cognitive complaints have higher levels of amyloid and tau in the brain [8]. Detecting these neuropathological changes in early stages is essential as studies have shown that the onset of these changes precede the onset of clinical AD symptoms by up to 15 years for CSF tau and 20 years for CSF $A\beta_{42}$ [12,13]. Furthermore, a study using data from ADNI found that the median time from estimated amyloid onset to clinical AD symptoms, as determined with a Clinical Dementia Rating (CDR) ≥ 1 , to be approximately 14 years [14].

Prior research has offered insight into the association between neuropathology and subjective cognitive decline. Amyloid positivity has been associated with higher levels of cognitive complaints even after accounting for depression and anxiety [15,16]. In addition, the severity of subjective cognitive complaints has been associated with higher amyloid burden [17], especially in the parietal and frontal cortices [18] and among *APOE* $\epsilon 4$ carriers [19]. Compared to amyloid, tau pathology is a stronger predictor of cognitive decline and progression to dementia [20–22]. However, there is limited research on the relationship between subjective cognitive complaints and tau pathology. One previous study found that

subjective cognitive complaints were associated with tau aggregation, particularly in the frontal and parietal regions [23], while other studies did not find associations with tau pathology [24,25]. Few studies have examined longitudinal outcomes of amyloid and tau pathology in association with subjective cognitive complaints.

Our study focuses on the following three research questions: first, what is the cross-sectional association between AD neuropathology and subjective cognitive complaints in cognitively normal individuals? Second, is AD neuropathology a predictor of subjective cognitive decline over time? Third, is AD neuropathology a stronger predictor of subjective cognitive complaints compared to neuropsychological assessment-based measures of memory among cognitively normal individuals? To address these questions, we assessed the relationship of subjective cognitive complaints as measured by the Cognitive Failures Questionnaire (CFQ) with global amyloid positivity and tau PET levels in regions that are known to exhibit early tau pathology.

2 Methods

2.1 Participants

We used data from 92 cognitively normal participants in the neuroimaging substudy of the Baltimore Longitudinal Study of Aging (BLSA) who had an ^{18}F -flortaucipir (FTP) PET scan to measure phosphorylated tau burden, a ^{11}C -Pittsburgh compound B (PiB) PET scan to measure fibrillar $\text{A}\beta$ burden, completed the Cognitive Failures Questionnaire (CFQ) [26], and received the California Verbal Learning Test (CVLT) [27]. We included the first FTP

PET assessment per participant in the analyses. For inclusion, participants needed to have a PiB PET within 2 years of their baseline FTP PET as well as a CFQ and a CVLT assessment within 6 months of their baseline FTP or PiB PET. For the longitudinal analyses, we examined all CFQ and CVLT assessments up to 5 years prior to and following the baseline FTP PET scan.

Participants were cognitively normal at all visits included in the analyses. Enrollment criteria for the neuroimaging substudy included having no evidence of central nervous system disease, severe cardiovascular or pulmonary disease, major psychiatric disorders, or metastatic cancer. Cognitively normal status was based on either (1) a Clinical Dementia Rating [28] of zero and ≤ 3 errors on the Blessed Information-Memory-Concentration Test [29], and therefore, the participant did not meet criteria for a consensus conference; or (2) the participant was determined to be cognitively normal based on thorough review of clinical and neuropsychological data at consensus conference.

Research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local institutional review boards (IRB) and the National Institutes of Health, and all participants gave written informed consent at each visit.

2.2 Cognitive measures

The CFQ evaluates subjective cognitive complaints, comprising 25 questions regarding common cognitive issues people may have in their everyday life. Examples of these

questions include: Do you fail to listen to people's names when you are meeting them? Do you have trouble making up your mind? Do you find you forget what you went to the store to buy? These questions are rated on a scale of how often the individual experiences these specific problems within the past two weeks, with 0 being "never" to 4 being "very often." Administration of the CFQ in the BLSA neuroimaging substudy began in 2000. Participants completed the questionnaire during their PET visit. We composed a variable to describe total score as a proportion of sum of scores divided by four times the total number of questions answered (total score / (4 × number of questions answered)). Higher scores represent greater subjective cognitive complaints.

We also calculated the three CFQ factor scores reflecting forgetfulness, distractibility, and false triggering using the loadings reported by Rast et al. [30]. The distractibility factor is defined by Rast et al. as "being absentminded or easily disturbed in one's focused attention in social situations," and is comprised of loadings from CFQ items such as "Do you fail to hear people speaking to you when you are doing something else?" and "Do you leave important letters unanswered for days?" The false triggering factor is defined as the "interrupted processing of sequences of cognitive and motor actions," and is comprised of loadings from CFQ items such as "Do you find you forget why you went from one part of the house to the other?" and "Do you find you forget what you went to the store to buy?" The forgetfulness factor is defined as "a tendency to let go from one's mind something known or planned" and is comprised of loadings from CFQ items such as "Do you find you forget people's names" and "Do you bump into people?" [30].

Verbal episodic memory was assessed by the CVLT. We quantified immediate recall as the sum of the number of correctly remembered items on the five learning trials. A memory composite score was calculated by averaging the z-scores (described below in the Statistical Analysis subsection) of the CVLT immediate recall and the long delay free recall. The Center for Epidemiological Studies – Depression (CES-D) [31] scale was used to quantify subjective depressive symptoms. All participants had a CES-D assessment within 2 weeks of baseline FTP PET.

2.3 PET imaging

To assess phosphorylated tau burden, FTP PET scans were acquired over 30 min on a Siemens High Resolution Research Tomograph (HRRT) scanner starting 75 min after an intravenous bolus injection of approximately 370 MBq of radiotracer. Dynamic images were reconstructed using ordered subset expectation-maximization to yield 6 time frames of 5 min each with approximately 2.5 mm full-width at half-maximum (FWHM) at the center of the field of view (image matrix = $256 \times 256 \times 107$, voxel size = $1.22 \times 1.22 \times 1.22$ mm³). Following time frame alignment, the 80–100 min average PET image was partial volume corrected using the region-based voxelwise method [32]. The corrected image was then used to compute standardized uptake value ratio (SUVR) images with inferior cerebellar gray matter as the reference region. FTP PET image analysis workflow is detailed in Ziontz et al. (2019) [33]. We computed the average bilateral SUVR in the entorhinal cortex (EC), hippocampus, parahippocampal gyrus, and the inferior temporal gyrus (ITG). One participant with outlying regional tau SUVRs was excluded from analyses (entorhinal SUVR of 2.0 and ITG SUVR of 2.7).

To assess fibrillar A β burden, PiB PET scans were obtained over 70 min on either a GE Advance or a Siemens HRRT scanner immediately following an intravenous bolus injection of approximately 555 MBq of radiotracer. Scans acquired on the GE Advance were reconstructed using filtered backprojection with a ramp filter to yield 33 time frames with approximately 4.5 mm FWHM at the center of the field of view (image matrix = 128 \times 128 \times 35, voxel size = 2 mm \times 2 mm \times 4.25 mm). Scans acquired on the Siemens HRRT were reconstructed using ordered subset expectation-maximization to yield 33 time frames with approximately 2.5 mm FWHM at the center of the field of view (image matrix = 256 \times 256 \times 207, voxel size = 1.22 mm \times 1.22 mm \times 1.22 mm). HRRT scans were smoothed with a 3 mm FWHM isotropic Gaussian kernel and then resampled to bring their spatial resolution closer to that of the GE Advance scans and match their voxel size. Following time frame alignment and co-registration with MRI, distribution volume ratio (DVR) images were computed using a spatially constrained simplified reference tissue model with cerebellar gray matter as the reference region [34]. Mean cortical A β burden was calculated as the average of the DVR values in cingulate, frontal, parietal (including precuneus), lateral temporal, and lateral occipital cortical regions, excluding the sensorimotor strip. PiB PET image analysis workflow is described in further detail in Bilgel et al. (2020) [35].

Leveraging longitudinal PiB PET data available on both GE Advance and HRRT scanners for 79 BLSA participants, we estimated the parameters of a linear model mapping mean cortical DVR values between the GE Advance and HRRT scanners and applied this mapping to all HRRT values to harmonize them with the GE Advance values. Individuals were categorized as PiB -/+ based on a mean cortical DVR threshold of 1.06, which was derived from a Gaussian mixture model fitted to harmonized mean cortical DVR values at baseline.

2.4 Statistical analysis

We fit linear mixed effects models to assess the associations between longitudinal cognitive outcomes and PET biomarkers at index visit, using a separate model for CFQ and CVLT and per each of the four tau PET ROIs, yielding a total of 8 models. Amyloid status (PiB -/+) and regional tau SUVR terms allowed for the examination of their cross-sectional associations with the outcome (CFQ or CVLT), and the interactions of each of these terms with time from PET allowed for the examination of their associations with the rate of change in the CFQ and CVLT outcomes. Age and CES-D at the time of the PET scan, sex, and years of education were included as covariates. We included a random intercept and slope per person. We confirmed our cross-sectional findings using linear regression models, fitted using data sets comprised of index visits only (Supplementary Material).

Prior to fitting the models, each cognitive outcome and tau SUVR variable was standardized by subtracting its mean and dividing by its standard deviation. The means and standard deviations for this standardization were computed using a larger cross-sectional BLSA data set comprised of cognitively normal individuals between the ages of 70 and 80, using the visit closest to age 75 per participant. (No standardization was needed for the amyloid status variable since it is binary.) As a result, the regression coefficients reported for the amyloid and tau variables are standardized coefficients.

Statistical analyses were conducted in R version 4.4.1 [36] using the `lmerTest` package [37].

2.5 Data Availability

Code for performing statistical analyses and generating figures is provided in an open repository (<https://gitlab.com/bilgelm/PET-and-CFQ>). Data from the BLSA are available upon request from the BLSA website (<https://www.blsa.nih.gov>). All requests are reviewed by the BLSA Data Sharing Proposal Review Committee.

3 Results

The sample consisted of 92 cognitively normal participants. Table 1 presents participant characteristics at index visit, which is defined by the requirement that they have a PiB PET within 2 years of their baseline FTP PET and a CFQ and a CVLT assessment within 6 months of their baseline FTP PET. A total of 243 visits were included for CFQ and 352 for CVLT (Figure 1).

Table 1: Participant characteristics at index visit. For continuous and categorical variables, we report the median and interquartile range and the N and percentage, respectively.

Characteristic	N = 92
Age (yr)	77 (70, 83)
Female	52 (57%)
White	71 (77%)
Education	18.00 (16.00, 18.00)
APOE ε4+	30 (33%)
PiB+	24 (26%)
Entorhinal tau SUVR	1.05 (0.96, 1.11)

Characteristic	N = 92
Hippocampal tau SUVR	1.30 (1.18, 1.45)
Parahippocampal tau SUVR	1.02 (0.94, 1.08)
ITG tau SUVR	1.22 (1.16, 1.28)
CES-D	4.0 (1.0, 8.0)
CFQ z-score	-0.11 (-0.86, 0.34)
Memory z-score	0.15 (-0.75, 0.77)
Number of CFQ visits	3 (1, 3)
Number of CVLT visits	4 (3, 5)
CFQ follow-up duration (yr)	3.37 (0.00, 4.50)
CVLT follow-up duration (yr)	5.03 (4.09, 6.71)

Abbreviations: APOE, apolipoprotein E; CES-D, Center for Epidemiological Studies - Depression; CFQ, Cognitive Failures Questionnaire; CVLT, California Verbal Learning Test; ITG, inferior temporal gyrus; PiB, Pittsburgh compound B; SUVR, standardized uptake value ratio.




Figure 1: Longitudinal CFQ (left) and memory (right) scores versus age.

3.1 Subjective cognitive complaints

In linear mixed effects models that included age, sex, years of education, CES-D, amyloid positivity, and regional tau pathology, we did not find any cross-sectional or longitudinal associations between amyloid positivity and CFQ. In contrast, higher parahippocampal tau SUVR was associated with higher CFQ at index visit (estimate = 0.178, SE = 0.0821, $p = 0.033$) (Table 2). Higher entorhinal tau SUVR at index visit was associated with an attenuated increase in CFQ over time (estimate = -0.064, SE = 0.0296, $p = 0.035$) (Figure 2).

Similar to our longitudinal finding based on the total CFQ score, we found a statistically significant association between higher entorhinal tau SUVR and attenuated increase over time in the CFQ false triggering and forgetfulness factors, whereas the cross-sectional association with parahippocampal tau SUVR was observed only for the CFQ distractibility score (Supplementary Material).

Table 2: Linear mixed effects model results where longitudinal CFQ total is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.138 (0.092)	0.069 (0.086)	0.178* (0.082)	0.009 (0.112)
Tau PET SUVR × Time	-0.064* (0.030)	-0.038 (0.025)	-0.027 (0.026)	-0.007 (0.040)

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$




Figure 2: Longitudinal CFQ trajectories by entorhinal tau SUVR z-score based on linear mixed effects model estimates.

3.2 Verbal episodic memory

In linear mixed effects models that included age, sex, years of education, CES-D, amyloid positivity and regional tau pathology, we did not find any cross-sectional or longitudinal associations between amyloid positivity and memory. Greater hippocampal tau SUVR was associated with a steeper decline in memory over time (estimate = -0.0293, SE = 0.0135, $p = 0.032$) (Table 5).

As a secondary analysis, we investigated the two CVLT components of the memory composite score in separate models (Supplementary Material). We found that greater tau SUVRS in the inferior temporal and parahippocampal gyri were associated with lower CVLT

immediate recall scores at index visit. Similar to our longitudinal finding based on memory composite score, we found that greater hippocampal tau SUVR was associated with a steeper decline in CVLT free recall long delay.

Table 3: Linear mixed effects model results where longitudinal memory is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.074 (0.114)	-0.187 (0.104)	-0.183 (0.101)	-0.182 (0.132)
Tau PET SUVR × Time	0.002 (0.016)	-0.029* (0.013)	-0.003 (0.014)	0.000 (0.018)

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

3.3 Comparison of CFQ and memory models

The marginal coefficients of determination (R^2) of the CFQ linear mixed effects models were more than double that of the memory models (0.32–0.35 vs. 0.14–0.17), indicating better model fit based on the fixed effects for the CFQ models. The conditional coefficients of determination, which incorporate random as well as fixed effects, of the CFQ models were 13% lower than those of the memory models (0.71–0.72 vs. 0.81–0.82).

To assess if the associations of amyloid and tau neuropathology with subjective cognitive complaints differ from their associations with verbal episodic memory, we tested the equality of the standardized regression coefficients between the CFQ and memory models using Seemingly Unrelated Regression Equations [38]. This analysis was limited to examining cross-sectional effects and we negated CFQ to make its direction consistent with that of memory. The differences between the standardized regression coefficients

estimated in the CFQ and memory models were not statistically significant for amyloid group or any of the regional tau SUVRs.

4 Discussion

We investigated the independent associations between PET measurements of two hallmark neuropathologies of AD and subjective cognitive complaints among cognitively normal older individuals, adjusting for age, sex, education, and depressive symptoms. Cross-sectionally, greater tau burden in the parahippocampal gyrus was associated with greater subjective cognitive complaints as assessed using the CFQ. Greater entorhinal tau SUVR was associated with an attenuated increase over a median follow-up duration of 3.4 years. In contrast, greater hippocampal SUVR was associated with a steeper decline in memory performance over a median follow-up duration of 5 years. When compared directly, we did not find statistically significant differences between subjective cognitive complaints and memory scores in terms of their associations with AD neuropathology.

The parahippocampal gyrus is part of the medial temporal lobe, a crucial region for memory processing. In agreement with our findings, several studies have also reported associations between tau in the medial temporal lobe and worse cognitive performance and cognitive decline among cognitively unimpaired individuals [39,40]. An ADNI study similarly found that self-reported complaints measured by the ECog (Measurement of Everyday Cognition) questionnaire were associated with parahippocampal tau burden as well as parietal, frontal, and global tau, although they found the strongest associations in the frontal lobe [23], whereas our study primarily analyzed regions in the temporal lobe.

However, this ADNI study included those with mild cognitive impairment whereas we restricted our analysis to include only cognitively unimpaired individuals.

The association between greater entorhinal tau and attenuated increases in CFQ over time may be explained by the possibility that subjective cognitive complaints exhibit steep increases early, prior to the elevation in entorhinal tau burden, with the rate of increase in subjective cognitive complaints tapering off later as entorhinal tau burden increases.

Larger studies examining both subjective cognitive complaints and tau burden longitudinally will be needed to test this hypothesis.

Compared to the total CFQ score, the CFQ factor score distractibility, but not false triggering or forgetfulness, had a similar magnitude of association, indicating that our cross-sectional finding may be driven by this factor [30]. Conversely, we found a statistically significant association between entorhinal tau and the longitudinal rate of change in the false triggering and forgetfulness factors, but not distractibility.

Our findings differ from previous reports in several ways. First, a Harvard Aging Brain Study found that entorhinal tau PET was associated with subjective cognitive decline as measured by the Memory Functioning Questionnaire, Everyday Cognition battery, and a 7-item questionnaire [41], whereas we did not find such an association with entorhinal tau.

In addition, we did not find a relationship between amyloid positivity and longitudinal change in memory, in contrast to longitudinal studies that have consistently indicated this association [42,43], including from the BLSA [44]. This is likely attributable to our inclusion of participants who remained cognitively normal throughout the longitudinal follow-up period included in these analyses and our limited sample size. Additionally, the present

study adjusted for regional tau pathology in the amyloid models, whereas the previous analysis in the BLSA did not. Second, unlike a previous BLSA analysis that found that elevated baseline entorhinal tau was linked to steeper memory decline prior to tau PET [33], we did not find an association between entorhinal tau and rate of memory decline. This difference may be attributed to the extent of CVLT follow-up in the present study compared with the Ziontz et al. study, as we limited the inclusion of CVLT scores to within five years of their index tau PET visit. In our models, amyloid and tau pathologies were assumed to have additive effects on the outcomes we investigated, but research suggests that their effects might be synergistic, with individuals having both pathologies exhibiting steeper cognitive decline. However, we were unable to investigate this synergistic effect due to our limited sample size.

This study has limitations. Our study accounted for certain factors that are associated with subjective cognitive complaints, such as severe psychiatric or neurological disorders, which are exclusion criteria for the BLSA, and depressive symptoms, which we adjusted for using CES-D as a covariate. However, there may be other conditions that affect subjective cognitive complaints that we did not account for, such as personality, medication use, substance use, and cultural background. For instance, one study found that CFQ was more associated with personality domains, such as conscientiousness and neuroticism, rather than objective cognitive performance [10]. In addition, our PET measures, particularly in the hippocampus, may be confounded by spill-over of non-specific binding signal in the choroid plexus. Lastly, the BLSA cohort is a highly educated and healthy sample and does not represent the general population.

Our study also has important strengths. This study extensively characterized participants through our available longitudinal CFQ measures. We made a direct comparison between subjective and objective measures by investigating associations of tau pathology with CFQ and CVLT. We also created a proportion variable to include those who had missing items on the questionnaire to maximize our sample size. In addition, we used subjective cognitive complaints as a continuous variable, unlike other studies that used subjective cognitive measures to identify participants as part of a subjective cognitive impairment group and then compared to healthy, MCI, and AD groups.

In conclusion, these findings add to our growing knowledge of the relationship between AD pathology and cognition. A previous BLSA study found that subjective cognitive complaints, also measured by the CFQ, were predictive of declining cognitive performance, particularly in verbal memory [6]. Other studies have found that those with subjective memory complaints combined with baseline AD neuropathology may be more likely to develop dementia and cognitive decline subsequently [45,46]. Therefore, our findings support the utility of including measures of subjective cognitive assessments as early indicators for AD. Early amyloid and tau accumulation may have cognitive effects that could be detected through subjective cognitive questionnaires such as the CFQ. This is of great clinical importance, as in routine clinical practice, amyloid and tau PET scans are not typically acquired; thus, subjective cognitive questionnaires might be a more practical screening tool to determine if further testing is warranted. Future studies investigating the relationship between AD neuropathology and subjective cognitive complaints can help clinicians detect those at risk for developing AD at the earliest opportunity and develop targeted interventions.

5 References

1. Jessen F, Amariglio RE, Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical alzheimer's disease. *Alzheimer's & Dementia*. 2014;10:844-852. doi:[10.1016/j.jalz.2014.01.001](https://doi.org/10.1016/j.jalz.2014.01.001)
2. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's and Dementia*. 2018;14:535-562. doi:[10.1016/j.jalz.2018.02.018](https://doi.org/10.1016/j.jalz.2018.02.018)
3. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of alzheimer's disease: Alzheimer's association workgroup. *Alzheimer's & Dementia*. Published online June 2024. doi:[10.1002/alz.13859](https://doi.org/10.1002/alz.13859)
4. Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective memory complaints in older persons may indicate poor cognitive function. *Journal of the American Geriatrics Society*. 2011;59:1612-1617. doi:[10.1111/j.1532-5415.2011.03543.x](https://doi.org/10.1111/j.1532-5415.2011.03543.x)
5. Park S, Lee JH, Lee J, et al. Interactions between subjective memory complaint and objective cognitive deficit on memory performances. *BMC geriatrics*. 2019;19:294. doi:[10.1186/s12877-019-1322-9](https://doi.org/10.1186/s12877-019-1322-9)
6. Hohman TJ, Beason-Held LL, Lamar M, Resnick SM. Subjective cognitive complaints and longitudinal changes in memory and brain function. *Neuropsychology*. 2011;25:125-130. doi:[10.1037/a0020859](https://doi.org/10.1037/a0020859)

7. Gifford KA, Liu D, Lu Z, et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. *Alzheimer's and Dementia*. 2014;10:319-327. doi:[10.1016/j.jalz.2013.02.007](https://doi.org/10.1016/j.jalz.2013.02.007)
8. Kryscio RJ, Abner EL, Cooper GE, et al. *Self-Reported Memory Complaints Implications from a Longitudinal Cohort with Autopsies*; 2014.
9. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. *Acta Psychiatrica Scandinavica*. 2014;130:439-451. doi:[10.1111/acps.12336](https://doi.org/10.1111/acps.12336)
10. Könen T, Karbach J. Self-reported cognitive failures in everyday life: A closer look at their relation to personality and cognitive performance. *Assessment*. 2020;27:982-995. doi:[10.1177/1073191118786800](https://doi.org/10.1177/1073191118786800)
11. Xu Y, Warwick J, Eramudugolla R, Huque H, Anstey KJ, Peters R. No clear associations between subjective memory concerns and subsequent change in cognitive function: The PATH through life study. *European Journal of Ageing*. 2022;19:1181-1188. doi:[10.1007/s10433-022-00694-2](https://doi.org/10.1007/s10433-022-00694-2)
12. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine*. 2012;367:795-804. doi:[10.1056/nejmoa1202753](https://doi.org/10.1056/nejmoa1202753)
13. Buchhave P, Minthon L, Zetterberg H, K Wallin sa, Blennow K, Hansson O. *Cerebrospinal Fluid Levels of-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia*. Vol 69.; 2012:98-106.

14. Betthausen TJ, Bilgel M, Kosciak RL, et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. *Brain*. 2022;145:4065-4079. doi:[10.1093/brain/awac213](https://doi.org/10.1093/brain/awac213)
15. Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline associated with amyloid positivity. *Alzheimer's and Dementia*. 2022;18:1832-1845. doi:[10.1002/alz.12512](https://doi.org/10.1002/alz.12512)
16. Pavisic IM, Lu K, Keuss SE, et al. Subjective cognitive complaints at age 70: Associations with amyloid and mental health. *Journal of Neurology, Neurosurgery and Psychiatry*. 2021;92:1215-1221. doi:[10.1136/jnnp-2020-325620](https://doi.org/10.1136/jnnp-2020-325620)
17. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. *Neuropsychologia*. 2012;50:2880-2886. doi:[10.1016/j.neuropsychologia.2012.08.011](https://doi.org/10.1016/j.neuropsychologia.2012.08.011)
18. Schwarz C, Lange C, Benson GS, et al. Severity of subjective cognitive complaints and worries in older adults are associated with cerebral amyloid- β load. *Frontiers in Aging Neuroscience*. 2021;13. doi:[10.3389/fnagi.2021.675583](https://doi.org/10.3389/fnagi.2021.675583)
19. Zwan MD, Villemagne VL, Doré V, et al. Subjective memory complaints in APOE ϵ 4 carriers are associated with high amyloid- β burden. *Journal of Alzheimer's Disease*. 2015;49:1115-1122. doi:[10.3233/JAD-150446](https://doi.org/10.3233/JAD-150446)
20. Ossenkoppele R, Binette AP, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nature Medicine*. 2022;28:2381-2387. doi:[10.1038/s41591-022-02049-x](https://doi.org/10.1038/s41591-022-02049-x)

21. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*. 2018;91:e859-e866. doi:[10.1212/WNL.0000000000006075](https://doi.org/10.1212/WNL.0000000000006075)
22. Bucci M, Chiotis K, Nordberg A. Alzheimer's disease profiled by fluid and imaging markers: Tau PET best predicts cognitive decline. *Molecular Psychiatry*. 2021;26:5888-5898. doi:[10.1038/s41380-021-01263-2](https://doi.org/10.1038/s41380-021-01263-2)
23. Swinford CG, Risacher SL, Charil A, Schwarz AJ, Saykin AJ. Memory concerns in the early alzheimer's disease prodrome: Regional association with tau deposition. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2018;10:322-331. doi:[10.1016/j.dadm.2018.03.001](https://doi.org/10.1016/j.dadm.2018.03.001)
24. Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. *Scientific Reports*. 2017;7. doi:[10.1038/s41598-017-08779-0](https://doi.org/10.1038/s41598-017-08779-0)
25. Thomas KR, Weigand AJ, Edwards LC, et al. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. *Alzheimer's research & therapy*. 2022;14:114. doi:[10.1186/s13195-022-01060-1](https://doi.org/10.1186/s13195-022-01060-1)
26. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. *British Journal of Clinical Psychology*. 1982;21:1-16. doi:[10.1111/j.2044-8260.1982.tb01421.x](https://doi.org/10.1111/j.2044-8260.1982.tb01421.x)
27. Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test - second edition adult version (CVLT-II). Published online 2000.

28. Morris JC. The Clinical Dementia Rating (CDR). *Neurology*. 1993;43(11).
doi:[10.1212/wnl.43.11.2412-a](https://doi.org/10.1212/wnl.43.11.2412-a)
29. Fuld P, Katzman R, Terry R, Bick K. Alzheimer's disease: Senile dementia and related disorders. Published online 1978.
30. Rast P, Zimprich D, Boxtel MV, Jolles J. Factor structure and measurement invariance of the cognitive failures questionnaire across the adult life span. *Assessment*. 2009;16(2):145-158. doi:[10.1177/1073191108324440](https://doi.org/10.1177/1073191108324440)
31. Radloff LS. The CES-D scale. *Applied Psychological Measurement*. 1977;1(3):385-401.
doi:[10.1177/014662167700100306](https://doi.org/10.1177/014662167700100306)
32. Thomas BA, Cuplov V, Bousse A, et al. PETPVC: A toolbox for performing partial volume correction techniques in positron emission tomography. *Physics in Medicine and Biology*. 2016;61:7975-7993. doi:[10.1088/0031-9155/61/22/7975](https://doi.org/10.1088/0031-9155/61/22/7975)
33. Ziontz J, Bilgel M, Shafer AT, et al. Tau pathology in cognitively normal older adults. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2019;11:637-645.
doi:[10.1016/j.dadm.2019.07.007](https://doi.org/10.1016/j.dadm.2019.07.007)
34. Zhou Y, Resnick SM, Ye W, et al. *Using a Reference Tissue Model with Spatial Constraint to Quantify [11C]Pittsburgh Compound B PET for Early Diagnosis of Alzheimer's Disease*. Vol 36.; 2007:298-312.
35. Bilgel M, Beason-Held L, An Y, Zhou Y, Wong DF, Resnick SM. Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid

PET imaging. *Journal of Cerebral Blood Flow and Metabolism*. 2020;40:288-297.

doi:[10.1177/0271678X19830537](https://doi.org/10.1177/0271678X19830537)

36. R Core Team. *R: A Language and Environment for Statistical Computing*. R

Foundation for Statistical Computing; 2024. <https://www.R-project.org/>

37. Kuznetsova A, Bruun Brockhoff P, Haubo Bojesen Christensen R. *lmerTest: Tests in*

Linear Mixed Effects Models.; 2020. <https://github.com/runehaubo/lmerTestR>

38. Zellner A. An efficient method of estimating seemingly unrelated regressions and

tests for aggregation bias. *Journal of the American Statistical Association*.

1962;57(298):348-368. doi:[10.1080/01621459.1962.10480664](https://doi.org/10.1080/01621459.1962.10480664)

39. Kwan ATH, Arfaie S, Therriault J, et al. Medial temporal tau predicts memory decline

in cognitively unimpaired elderly. *Brain Communications*. 2023;5.

doi:[10.1093/braincomms/fcac325](https://doi.org/10.1093/braincomms/fcac325)

40. Marks SM, Lockhart SN, Baker SL, Jagust WJ. Tau and β -amyloid are associated with

medial temporal lobe structure, function, and memory encoding in normal aging. *Journal of*

Neuroscience. 2017;37:3192-3201. doi:[10.1523/JNEUROSCI.3769-16.2017](https://doi.org/10.1523/JNEUROSCI.3769-16.2017)

41. Buckley RF, Hanseeuw B, Schultz AP, et al. Region-specific association of subjective

cognitive decline with tauopathy independent of global β -amyloid burden. *JAMA Neurology*.

2017;74:1455-1463. doi:[10.1001/jamaneurol.2017.2216](https://doi.org/10.1001/jamaneurol.2017.2216)

42. Baker JE, Lim YY, Pietrzak RH, et al. Cognitive impairment and decline in cognitively

normal older adults with high amyloid- β : A meta-analysis. *Alzheimer's and Dementia*:

Diagnosis, Assessment and Disease Monitoring. 2017;6:108-121.

doi:[10.1016/j.dadm.2016.09.002](https://doi.org/10.1016/j.dadm.2016.09.002)

43. Mortamais M, Ash JA, Harrison J, et al. Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. *Alzheimer's and Dementia*. 2017;13:468-492.

doi:[10.1016/j.jalz.2016.06.2365](https://doi.org/10.1016/j.jalz.2016.06.2365)

44. Bilgel M, An Y, Helpfrey J, et al. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. *Brain*. 2018;141:2475-2485.

doi:[10.1093/brain/awy150](https://doi.org/10.1093/brain/awy150)

45. Antonell A, Fortea J, Rami L, et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. *Journal of Neural Transmission*. 2011;118:259-262. doi:[10.1007/s00702-010-](https://doi.org/10.1007/s00702-010-0534-0)

[0534-0](https://doi.org/10.1007/s00702-010-0534-0)

46. Selnes P, Aarsland D, Bjørnerud A, et al. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. *Journal of Alzheimer's Disease*. 2013;33:723-736. doi:[10.3233/JAD-2012-121603](https://doi.org/10.3233/JAD-2012-121603)

doi:[10.3233/JAD-2012-121603](https://doi.org/10.3233/JAD-2012-121603)

6 Acknowledgments

We are grateful to the BLSA participants and staff for their dedication to these studies. We thank Dr. Andrea Shafer for her statistical suggestions in the early stages of our analyses.

This research was supported by the Intramural Research Program of the National Institute on Aging, NIH.

Supplementary Material

1.1 Participant selection

Of 113 participants who underwent both amyloid and tau PET imaging, 103 had at least one cognitively normal visit where these two scans were within 2 years of each other. 101 of these participants also had at least one visit with a CES-D assessment within 2 weeks of PET. Of these, 97 had at least one visit where they were cognitively normal at the time of their CFQ assessment. 92 had at least one visit where they had both CFQ and CVLT assessments within 6 months of PET.

1.2 Linear regression models

Linear regression, using data sets comprised of index visits only, was used to confirm our cross-sectional associations in the linear mixed effects models. The estimates were similar to what we reported based on the linear mixed effects models.

1.2.1 Subjective cognitive complaints




Figure 3: CFQ score at index visit versus regional tau SUVR.

Table 4: Linear regression model results where CFQ score is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.166	0.101	0.222*	0.019
	(0.100)	(0.095)	(0.089)	(0.119)

* p < 0.05, ** p < 0.01, *** p < 0.001

1.2.2 Verbal episodic memory




Figure 4: CVLT immediate recall score at index visit versus regional tau SUVR.

Table 5: Linear regression model results where CVLT is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.060	-0.126	-0.179	-0.238
	(0.131)	(0.122)	(0.117)	(0.151)

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

1.3 Other linear mixed effects models

1.3.1 Subjective cognitive complaints

Table 6: Linear mixed effects model results where longitudinal CFQ forgetfulness is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.109	0.080	0.140	0.017
	(0.094)	(0.088)	(0.085)	(0.114)
Tau PET SUVR × Time	-0.065*	-0.050	-0.036	-0.024
	(0.032)	(0.027)	(0.028)	(0.042)

* p < 0.05, ** p < 0.01, *** p < 0.001

Table 6: Linear mixed effects model results where longitudinal CFQ distractibility is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.147	0.091	0.202*	0.043
	(0.094)	(0.088)	(0.083)	(0.114)
Tau PET SUVR × Time	-0.047	-0.025	-0.014	0.003

EntorhinalHippocampusParahippocampallTG				
<hr/>				
	(0.027)	(0.023)	(0.024)	(0.037)
<hr/>				

* p < 0.05, ** p < 0.01, *** p < 0.001

Table 6: Linear mixed effects model results where longitudinal CFQ false triggering is the outcome.

EntorhinalHippocampusParahippocampallTG				
<hr/>				
Tau PET SUVR	0.114	0.021	0.133	-0.021
	(0.090)	(0.085)	(0.081)	(0.110)
Tau PET SUVR × Time-0.069*	-0.043	-0.030	-0.007	
	(0.031)	(0.026)	(0.027)	(0.041)
<hr/>				

* p < 0.05, ** p < 0.01, *** p < 0.001

1.3.2 Verbal episodic memory

Table 7: Linear mixed effects model results where longitudinal CVLT immediate recall is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	TG
Tau PET SUVR	-0.101 (0.119)	-0.186 (0.109)	-0.211* (0.106)	-0.285* (0.137)
Tau PET SUVR × Time0.000		-0.026 (0.018)	-0.004 (0.016)	-0.020 (0.021)

* p < 0.05, ** p < 0.01, *** p < 0.001

Table 7: Linear mixed effects model results where longitudinal CVLT free recall long delay is the outcome.

	Entorhinal	Hippocampus	Parahippocampal	TG
Tau PET SUVR	-0.049 (0.114)	-0.189 (0.103)	-0.157 (0.102)	-0.079 (0.134)
Tau PET SUVR × Time0.004		-0.033* (0.017)	-0.003 (0.016)	0.020 (0.020)

* p < 0.05, ** p < 0.01, *** p < 0.001

